#South Korea #Seoul #Sanofi #ADEL-Y01 #Alzheimer's therapy

ADEL and Sanofi Forge a Groundbreaking Partnership

ADEL, Inc., a biopharmaceutical company with a focus on treating neurodegenerative diseases, has announced a significant licensing agreement with Sanofi, a leading global healthcare company. This partnership involves the exclusive worldwide rights for ADEL-Y01, an innovative investigational treatment aimed at Alzheimer's Disease.

Financial Terms of the Agreement

The deal outlines a potential total value reaching up to $1.04 billion, with ADEL receiving an upfront payment of $80 million. In addition, ADEL could secure further payments based on the achievement of certain development and commercial milestones. They would also benefit from tiered royalties amounting to double-digit percentages on net sales, enhancing the overall financial viability of the partnership.

The Innovation Behind ADEL-Y01

What sets ADEL-Y01 apart from existing Alzheimer’s treatments is its unique targeting mechanism. The therapy is a humanized monoclonal antibody that specifically targets tau protein acetylated at Lysine-280 (acK280). Unlike traditional therapies that inhibit total tau, ADEL-Y01 focuses on blocking the aggregation and spread of toxic tau species, which are known to be crucial in the progression of Alzheimer's. Importantly, this innovative approach preserves the normal functionalities of standard microtubule-associated tau.

ADEL has utilized a proprietary research platform dedicated to the development of therapies for neurodegenerative diseases, leading to the discovery of ADEL-Y01. Since 2020, it has been co-developed with Oscotec Inc. The therapy is currently in Phase 1 clinical trials, initiated under an Investigational New Drug (IND) application approved by the U.S. Food and Drug Administration (FDA).

A Strong Strategic Collaboration

Seung-Yong Yoon, CEO of ADEL, expressed enthusiasm about this partnership, stating, “This strategic collaboration with Sanofi underscores our technological expertise and highlights the immense promise of ADEL-Y01. Combining our scientific insights with Sanofi's proven development capabilities will allow us to expedite the availability of this disease-modifying therapy to Alzheimer’s patients globally.”

Erik Wallstroem, Sanofi's Global Head of Development in Multiple Sclerosis and Neurology, emphasized the innovative nature of ADEL’s approach, remarking, “ADEL's novel strategy targeting tau acetylation brings a promising and distinct mechanism that addresses Alzheimer's disease's root causes. We are eager to progress ADEL-Y01 through clinical development to bring renewed hope to those affected by this debilitating condition.”

About ADEL, Inc.

ADEL, Inc. was founded in 2016 by Professor Seung-Yong Yoon at the Asan Medical Center, University of Ulsan College of Medicine. The company is dedicated to developing groundbreaking therapies for neurodegenerative diseases by leveraging proprietary technology that targets critical protein modifications and aggregation. Their goal is to secure a position as a global leader in the field of neurodegenerative disease treatment, with ADEL-Y01 being a cornerstone in their pipeline of innovative solutions.

This strategic licensing agreement marks a pivotal moment for both ADEL and Sanofi as they seek to revolutionize treatment options for Alzheimer's Disease, providing hope and improved outcomes for patients worldwide.